Kaiser Health News/NPR Examine U.S. FDA’s Priority Review Voucher Program

Kaiser Health News/NPR: Are Golden Tickets That Speed Drugs Through FDA Worthwhile?
“…Members of Congress, the pharmaceutical industry, and rare disease advocates have passionately supported [priority review] vouchers as a way to spur development of drugs for rare and neglected diseases. But skeptics, including FDA officials and some academics, have questioned whether the program is paying off…” (Tribble, 9/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.